Rady A. Johnson Sells 8,000 Shares of Pfizer Inc. (PFE) Stock

Pfizer Inc. (NYSE:PFE) EVP Rady A. Johnson sold 8,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $37.07, for a total transaction of $296,560.00. Following the sale, the executive vice president now directly owns 46,963 shares in the company, valued at approximately $1,740,918.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Pfizer Inc. (PFE) traded down $0.02 during trading hours on Friday, hitting $36.54. The stock had a trading volume of 19,179,700 shares, compared to its average volume of 15,820,000. The firm has a market cap of $217,800.00, a P/E ratio of 22.42, a PEG ratio of 2.46 and a beta of 1.01. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. Pfizer Inc. has a fifty-two week low of $30.90 and a fifty-two week high of $37.35.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.02. The business had revenue of $13.17 billion during the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The business’s revenue was up .9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.61 EPS. equities analysts forecast that Pfizer Inc. will post 2.59 EPS for the current year.

Pfizer declared that its Board of Directors has authorized a stock repurchase plan on Monday, December 18th that permits the company to repurchase $10.00 billion in shares. This repurchase authorization permits the biopharmaceutical company to buy shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company’s management believes its stock is undervalued.

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 3.72%. The ex-dividend date of this dividend is Thursday, February 1st. This is an increase from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s payout ratio is 78.53%.

PFE has been the topic of a number of analyst reports. BMO Capital Markets reiterated a “buy” rating and issued a $39.00 price objective (up from $37.00) on shares of Pfizer in a research report on Thursday, October 19th. Barclays set a $38.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, October 11th. ValuEngine upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Friday, October 6th. Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price objective on the stock in a research report on Tuesday, October 3rd. Finally, Sanford C. Bernstein set a $39.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Tuesday, September 19th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $38.83.

Hedge funds have recently made changes to their positions in the stock. Shine Investment Advisory Services Inc. acquired a new position in Pfizer in the 2nd quarter valued at about $102,000. Mckinley Capital Management LLC Delaware purchased a new stake in Pfizer in the 2nd quarter valued at about $103,000. D. Scott Neal Inc. grew its holdings in Pfizer by 19.3% in the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 504 shares during the period. Franklin Parlapiano Turner & Welch LLC purchased a new stake in Pfizer in the 1st quarter valued at about $121,000. Finally, Herndon Capital Management LLC purchased a new stake in Pfizer in the 2nd quarter valued at about $120,000. 69.74% of the stock is owned by hedge funds and other institutional investors.

WARNING: This report was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://ledgergazette.com/2018/01/13/pfizer-inc-pfe-evp-sells-296560-00-in-stock.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Insider Buying and Selling by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply